Literature DB >> 22012889

A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Garrett M Dancik1, Yuanbin Ru, Charles R Owens, Dan Theodorescu.   

Abstract

Experimental work on human cancer cell lines often does not translate to the clinic. We posit that this is because some cells undergo changes in vitro that no longer make them representative of human tumors. Here, we describe a novel alignment method named Spearman's rank correlation classification method (SRCCM) that measures similarity between cancer cell lines and human tumors via gene expression profiles, for the purpose of selecting lines that are biologically relevant. To show utility, we used SRCCM to assess similarity of 36 bladder cancer lines with 10 epithelial human tumor types (N = 1,630 samples) and with bladder tumors of different stages and grades (N = 144 samples). Although 34 of 36 lines aligned to bladder tumors rather than other histologies, only 16 of 28 had SRCCM assigned grades identical to that of their original source tumors. To evaluate the clinical relevance of this approach, we show that gene expression profiles of aligned cell lines stratify survival in an independent cohort of 87 bladder patients (HR = 3.41, log-rank P = 0.0077) whereas unaligned cell lines using original tumor grades did not. We repeated this process on 22 colorectal cell lines and found that gene expression profiles of 17 lines aligning to colorectal tumors and selected based on their similarity with 55 human tumors stratified survival in an independent cohort of 177 colorectal cancer patients (HR = 2.35, log-rank P = 0.0019). By selecting cell lines that reflect human tumors, our technique promises to improve the clinical translation of laboratory investigations in cancer.

Entities:  

Mesh:

Year:  2011        PMID: 22012889      PMCID: PMC3242880          DOI: 10.1158/0008-5472.CAN-11-2427

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Defining optimal therapy for muscle invasive bladder cancer.

Authors:  Harry W Herr; Zohar Dotan; S Machele Donat; Dean F Bajorin
Journal:  J Urol       Date:  2007-02       Impact factor: 7.450

2.  Widespread intraspecies cross-contamination of human tumor cell lines arising at source.

Authors:  R A MacLeod; W G Dirks; Y Matsuo; M Kaufmann; H Milch; H G Drexler
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

Review 3.  Human cancer cell lines: fact and fantasy.

Authors:  J R Masters
Journal:  Nat Rev Mol Cell Biol       Date:  2000-12       Impact factor: 94.444

Review 4.  Tackling the widespread and critical impact of batch effects in high-throughput data.

Authors:  Jeffrey T Leek; Robert B Scharpf; Héctor Corrada Bravo; David Simcha; Benjamin Langmead; W Evan Johnson; Donald Geman; Keith Baggerly; Rafael A Irizarry
Journal:  Nat Rev Genet       Date:  2010-09-14       Impact factor: 53.242

5.  False leukemia-lymphoma cell lines: an update on over 500 cell lines.

Authors:  H G Drexler; W G Dirks; Y Matsuo; R A F MacLeod
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

6.  Studies of the mechanism of action of platinum(II) complexes with potent cytotoxicity in human cancer cells.

Authors:  Anwen M Krause-Heuer; Renate Grünert; Sybill Kühne; Magdalena Buczkowska; Nial J Wheate; Delphine D Le Pevelen; Leanne R Boag; Dianne M Fisher; Jana Kasparkova; Jaroslav Malina; Patrick J Bednarski; Viktor Brabec; Janice R Aldrich-Wright
Journal:  J Med Chem       Date:  2009-09-10       Impact factor: 7.446

Review 7.  Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.

Authors:  J K Peterson; P J Houghton
Journal:  Eur J Cancer       Date:  2004-04       Impact factor: 9.162

8.  ArrayExpress update--an archive of microarray and high-throughput sequencing-based functional genomics experiments.

Authors:  Helen Parkinson; Ugis Sarkans; Nikolay Kolesnikov; Niran Abeygunawardena; Tony Burdett; Miroslaw Dylag; Ibrahim Emam; Anna Farne; Emma Hastings; Ele Holloway; Natalja Kurbatova; Margus Lukk; James Malone; Roby Mani; Ekaterina Pilicheva; Gabriella Rustici; Anjan Sharma; Eleanor Williams; Tomasz Adamusiak; Marco Brandizi; Nataliya Sklyar; Alvis Brazma
Journal:  Nucleic Acids Res       Date:  2010-11-10       Impact factor: 16.971

9.  Alterations of TP53 in microdissected transitional cell carcinoma of the human urinary bladder: high frequency of TP53 accumulation in the absence of detected mutations is associated with poor prognosis.

Authors:  R Abdel-Fattah; C Challen; T R Griffiths; M C Robinson; D E Neal; J Lunec
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours.

Authors:  J E Nutt; J K Mellon; K Qureshi; J Lunec
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

View more
  15 in total

1.  An Osteopontin/CD44 Axis in RhoGDI2-Mediated Metastasis Suppression.

Authors:  Mansoor Ahmed; Joseph L Sottnik; Garrett M Dancik; Divya Sahu; Donna E Hansel; Dan Theodorescu; Martin A Schwartz
Journal:  Cancer Cell       Date:  2016-09-01       Impact factor: 31.743

2.  CNpare: matching DNA copy number profiles.

Authors:  Blas Chaves-Urbano; Barbara Hernando; Maria J Garcia; Geoff Macintyre
Journal:  Bioinformatics       Date:  2022-05-31       Impact factor: 6.931

3.  UM-SCC-103: a unique tongue cancer cell line that recapitulates the tumorigenic stem cell population of the primary tumor.

Authors:  John H Owen; Samantha J Hauff; Alice L Tang; Martin P Graham; Michael J Czerwinski; Marcella Kaddoura; Silvana Papagerakis; Carol R Bradford; Thomas E Carey; Mark E P Prince
Journal:  Ann Otol Rhinol Laryngol       Date:  2014-05-09       Impact factor: 1.547

4.  Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.

Authors:  Kristi L Hoffman; Seth P Lerner; Carolyn L Smith
Journal:  Horm Cancer       Date:  2012-09-11       Impact factor: 3.869

5.  Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.

Authors:  Steven C Smith; Alexander S Baras; Charles R Owens; Garrett Dancik; Dan Theodorescu
Journal:  Cancer Res       Date:  2012-05-14       Impact factor: 12.701

6.  Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization.

Authors:  Hong Wang; Yuanbin Ru; Marta Sanchez-Carbayo; Xuejiao Wang; Jeffrey S Kieft; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2013-04-10       Impact factor: 12.531

7.  GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis.

Authors:  Neeraj Agarwal; Garrett M Dancik; Andrew Goodspeed; James C Costello; Charles Owens; Jason E Duex; Dan Theodorescu
Journal:  Cancer Res       Date:  2016-06-16       Impact factor: 12.701

8.  Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.

Authors:  Jaine K Blayney; Timothy Davison; Nuala McCabe; Steven Walker; Karen Keating; Thomas Delaney; Caroline Greenan; Alistair R Williams; W Glenn McCluggage; Amanda Capes-Davis; D Paul Harkin; Charlie Gourley; Richard D Kennedy
Journal:  Nucleic Acids Res       Date:  2016-06-28       Impact factor: 16.971

9.  Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].

Authors:  Karoly Szepeshazi; Andrew V Schally; Gunhild Keller; Norman L Block; Daniel Benten; Gabor Halmos; Luca Szalontay; Irving Vidaurre; Miklos Jaszberenyi; Ferenc G Rick
Journal:  Oncotarget       Date:  2012-07

10.  Drug sensitivity in cancer cell lines is not tissue-specific.

Authors:  Samira Jaeger; Miquel Duran-Frigola; Patrick Aloy
Journal:  Mol Cancer       Date:  2015-02-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.